National Institute of Mental Health, Bethesda, MD 20892, USA.
Sci Transl Med. 2012 Oct 10;4(155):155ps19. doi: 10.1126/scitranslmed.3004873.
There has been a steady retreat by the private sector away from developing medications for mental disorders. This retreat comes just as research is identifying new molecular targets, new clinical targets, and new uses of current treatments that may serve as the basis for the next generation of treatments for mental disorders.
私营部门开发精神障碍药物的力度一直在稳步减弱。这种撤退正值研究人员确定新的分子靶点、新的临床靶点以及当前治疗方法的新用途之际，这些可能为下一代精神障碍治疗方法奠定基础。
